Loading...
Images of Nurit Livnah
(0 from 0 )News
Early-stage Parkinson’s Phase 3 Trial Shows Promise for ...
parkinsonsnewstoday.com
“We believe P2B001 has the potential to become a leading therapy for early stage PD,” Nurit Livnah, CEO of Pharma Two B, said in a press release. “Pharma Two B is focused on successfully completing our Phase 3 as planned and preparing for product launch in
Successful results in Phase IIb study for early PD treatment |...
www.acsh.org
Jul 01, · Moreover, P2B001 provided benefits similar to those observed with the higher doses currently prescribed to PD patients. This means that with P2B001, PD patients may be able to achieve clinical benefits comparable to current treatments but with lower doses and less risk of serious side effects, said Pharma Two B CEO, Dr. Nurit Livnah.
Company News - Biotechgate
www.croatianbiotech.com
... in a sustained release formulation has synergistic effects leading to notable efficacy and a very good safety profile," said Pharma Two B CEO, Dr. Nurit Livnah.
Pharma Two B raises $30 million for Parkinson's treatment trialjewishbusinessnews.com › › pharma-two-b-raises-30-milli...
jewishbusinessnews.com
Pharma Two B CEO Dr. Nurit Livnah said, “The phase IIb trial we conducted for P2B001 has met all primary and secondary end-points and ...
sorted by relevance / date